Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms

Leukemia Research

Volumn 39, Issue 1, 2015, Pages 82-87

  Jones, Amy V ^a,b   Ward, Daniel ^b   Lyon, Matthew ^b   Leung, William ^a,b   Callaway, Alison ^b   Chase, Andrew ^a,b   Dent, Carolyn L ^b   White, Helen E ^a,b   Drexler, Hans G ^c   Nangalia, Jyoti ^d   Mattocks, Chris ^a,b   Cross, Nicholas C P ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SALISBURY NHS FOUNDATION TRUST   (United Kingdom)

^c LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

CALR; MARIMO; MPN

Indexed keywords

DNA; NUCLEOTIDE; CALRETICULIN; CALRETICULIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CALR GENE; DNA DETERMINATION; GENE DELETION; GENETIC SCREENING; HETEROZYGOSITY; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; LIMIT OF DETECTION; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE NEOPLASM; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; SANGER SEQUENCING; SEQUENCE ANALYSIS; TUMOR GENE; ALLELE; CLINICAL TRIAL; FEMALE; GENETIC LINKAGE; GENETICS; HEMATOLOGIC DISEASE; MALE; MUTATION; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PROCEDURES;

ALLELES; CALRETICULIN; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LOD SCORE; MALE; MUTATION; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS;

EID: 84920608563     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.11.019     Document Type: Article

References (26)

1. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(July (5)):937-951.
2. Cross N.C. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011, 2011:208-214.
3. Scott L.M. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011, 86(August (8)):668-676.
4. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 3(July (7)):e270.
5. Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013, 369(December (25)):2391-2405.
6. Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013, 369(December (25)):2379-2390.
7. Tefferi A., Pardanani A., Genetics: 1. CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol 2014, 11(March (3)):125-126.
8. Rumi E., Pietra D., Ferretti V., Klampfl T., Harutyunyan A.S., Milosevic J.D., et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014, 123(March (10)):1544-1551.
9. Rotunno G., Mannarelli C., Guglielmelli P., Pacilli A., Pancrazzi A., Pieri L., et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014, 123(March (10)):1552-1555.
10. Tefferi A., Lasho T.L., Finke C.M., Knudson R.A., Ketterling R., Hanson C.H., et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014, 28(July (7)):1472-1477.
11. Tefferi A., Guglielmelli P., Lasho T.L., Rotunno G., Finke C., Mannarelli C., et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014, 28(July (7)):1494-1500.
12. Bench A.J., White H.E., Foroni L., Godfrey A.L., Gerrard G., Akiki S., et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol 2013, 160(January (1)):25-34.
13. Yoshida H., Kondo M., Ichihashi T., Hashimoto N., Inazawa J., Ohno R., et al. A novel myeloid cell line. Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: consistent chromosomal abnormalities and temporary C-MYC gene amplification. Cancer Genet Cytogenet 1998, 100(January (1)):21-24.
14. Jones A.V., Cross N.C., White H.E., Green A.R., Scott L.M. Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica 2008, 93(October (10)):1560-1564.
15. Aguiar R.C., Chase A., Coulthard S., Macdonald D.H., Carapeti M., Reiter A., et al. Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. Blood 1997, 90(October (8)):3130-3135.
16. Doring A., Weese D., Rausch T., Reinert K. SeqAn an efficient, generic C++ library for sequence analysis. BMC Bioinform. 2008, 9:11.
17. DePristo M.A., Banks E., Poplin R., Garimella K.V., Maguire J.R., Hartl C., et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011, 43(May (5)):491-498.
18. McLaren W., Pritchard B., Rios D., Chen Y., Flicek P., Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP effect predictor. Bioinformatics 2010, 26(August (16)):2069-2070.
19. Thorvaldsdottir H., Robinson J.T., Mesirov J.P. Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013, 14(March (2)):178-192.
20. Wittwer C.T., Reed G.H., Gundry C.N., Vandersteen J.G., Pryor R.J. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 2003, 49(June (6 Pt 1)):853-860.
21. Murugesan G., Aboudola S., Szpurka H., Verbic M.A., Maciejewski J.P., Tubbs R.R., et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 2006, 125(April (4)):625-633.
22. Rapado I., Grande S., Albizua E., Ayala R., Hernandez J.A., Gallardo M., et al. High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. J Mol Diagn 2009, 11(March (2)):155-161.
23. Allen C., Lambert J.R., Linch D.C., Gale R.E. X-chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations. Blood 2014, 124(September (13)):2091-2093.
24. Tefferi A., Wassie E.A., Guglielmelli P., Gangat N., Belachew A.A., Lasho T.L., et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 2014, 89(August (8)):E121-E124.
25. Jones A.V., Silver R.T., Waghorn K., Curtis C., Kreil S., Zoi K., et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2006, 107(April (8)):3339-3341.
26. Kiladjian J.J., Cassinat B., Chevret S., Turlure P., Cambier N., Roussel M., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112(October (8)):3065-3072.